Pharmaceuticals

Hvsen Biotech

Hvsen Biotech released FY2026 Q1 earnings on April 27 After-Market BJT, actual revenue CNY 458.22 M, actual EPS CNY 0.3834

Hvsen Biotech FY2026 Q1 Earnings Release on April 28 After-Market (BJT)

Hvsen Biotech released FY2025 earnings on April 16 After-Market (BJT), actual revenue CNY 1.681 B (forecast CNY 2.135 B), actual EPS CNY 1.2918 (forecast CNY 0.89)

Hvsen Biotech released FY2025 Q4 earnings on April 16 After-Market (BJT), actual revenue CNY 421.71 M, actual EPS CNY 0.2866

Hvsen Biotech to Release FY2025 Earnings on April 17 After-Market (BJT), Forecast Revenue CNY 2.135 B, EPS CNY 0.89

Hvsen Biotech released FY2025 Q3 earnings on October 27 After-Market BJT, actual revenue CNY 437.33 M, actual EPS CNY 0.3495

Hvsen Biotech released FY2025 9 Months earnings on October 27 After-Market (BJT), actual revenue CNY 1.26 B, actual EPS CNY 0.9854

Hvsen Biotech to Release FY2025 Q3 Earnings on October 28 After-Market (BJT)

Huisheng Biology Increases Investment in Pet Medicine R&D and Market Channels

Huisheng Bio's Pet Drug Enconazole Has Obtained Production License and Launched

Huisheng Biotech Subsidiary Invests in Veterinary Drug Production Line Upgrades

Hvsen Biotech released FY2025 Semi-Annual earnings on August 5 During-Market (BJT), actual revenue CNY 822.2 M, actual EPS CNY 0.6622

Hvsen Biotech released FY2025 Q2 earnings on August 5 During-Market (BJT), actual revenue CNY 423.13 M, actual EPS CNY 0.3863

Hvsen Biotech to Release FY2025 Semi-Annual Earnings on August 6, 2025 (BJT)

Huisheng Bio fully holds the establishment of Wuhan Yuanhe Zhiseng Biotechnology Co., Ltd.

Southwest Securities Issues Buy Rating on Huisheng Bio

RBSB Secretary Explains Controlling Shareholder's Rights Issue Plan

Huisheng Biology Maintains B Rating in ESG, Overall Ranking Declines

Huisheng Bio's Stock Issuance Application Approved by Shenzhen Stock Exchange

Huisheng Bio's raw material technological reform project has been put into production

300871

Hvsen Biotech announced an investment of 1 billion yuan to build a synthetic biology manufacturing project in Xinjiang, which will be carried out in three phases. The project aims to enhance capacity and efficiency, aligns with the industrial policies of the western region, and enjoys tax incentives. The project faces risks related to the market, technology, and international trade, and the company will respond through market monitoring, R&D investment, and expanding overseas channels

36Kr

Hvsen Biotech: Invests 1 billion yuan to build a synthetic biology manufacturing project in Xinjiang

Hvsen Biotech released its Q3 2025 report, with operating revenue for the first three quarters reaching 1.26 billion yuan, a year-on-year increase of 58.92%; net profit attributable to the parent company was 188 million yuan, a year-on-year increase of 494.28%; net profit excluding non-recurring gains and losses was 166 million yuan, a year-on-year increase of 611.92%; basic earnings per share were 1.0134 yuan

Zhitong

Hvsen Biotech released its performance for the first three quarters, with a net profit attributable to the parent company of 188 million yuan, an increase of 494.28%

Wuhan Hvsen Biotech Co., Ltd.'s subsidiary Hubei Hvsen Biotech Co., Ltd. has obtained a new veterinary drug registration certificate from the Ministry of Agriculture and Rural Affairs for its "Yinqiao Lianqin Oral Solution." This drug is classified as a Class III new veterinary drug, primarily used for the prevention and treatment of respiratory diseases in chickens. Although the successful development of this product demonstrates the company's innovation capabilities, its short-term impact on performance is limited, and investors should be aware of the associated risks

Hvsen Biotech: Subsidiary "Yinqiao Lanjin Oral Solution" Obtains New Veterinary Drug Registration Certificate

Hvsen Biotech stated on the investor interaction platform that the pet medicine sector is one of the key development directions of the company. The company is adjusting resource allocation and increasing investment in the research and development of pet medicines and the construction of market channels. It has established an independent and specialized pet medicine R&D team, and in the first half of this year, it has obtained 7 pet product approvals, greatly expanding its pet product line. The company's pet medicines mainly involve sub-sectors such as pet deworming, antipyretic and analgesic medications, dermatological drugs, internal medicine diseases, and functional health products

Hvsen Biotech: In the first half of this year, it has obtained 7 pet product approvals, greatly expanding its pet product line

Hvsen Biotech announced that the company will invest 170 million yuan to implement a green equipment technological transformation project for veterinary raw materials, upgrading the existing production line in two phases. The project aims to introduce efficient, energy-saving, and automated equipment to enhance production capacity, expand the fermentation product pipeline, and optimize the product structure

Hvsen Biotech plans to invest CNY 170 million to implement a green equipment technological transformation project for veterinary raw materials

According to the Zhitong Finance APP, Hvsen Biotech released its semi-annual report for 2025, showing an operating income of 822 million yuan, a year-on-year increase of 88.45%. The net profit attributable to shareholders of the listed company was 117 million yuan. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 99.301 million yuan. The basic earnings per share were 0.6622 yuan. In addition, it plans to distribute a cash dividend of 1.00 yuan (including tax) for every 10 shares to all shareholders

Hvsen Biotech released its performance for the first half of the year, turning a loss into a profit of 117 million yuan

According to the Qichacha APP, recently, Wuhan Yuanhe Zhisheng Biotechnology Co., Ltd. was established, with a business scope that includes: artificial intelligence industry application system integration services; artificial intelligence dual innovation service platform; artificial intelligence basic resources and technology platform, etc. Qichacha's equity penetration shows that the company is wholly owned by Hvsen Biotech

Hvsen Biotech establishes a new subsidiary, including AI-related businesses

On the morning of July 9th, Hvsen Biotech announced that its application for the issuance of shares to specific targets has been accepted by the Shenzhen Stock Exchange

Hvsen Biotech: Application for the issuance of shares to specific objects has been accepted by the Shenzhen Stock Exchange

Hvsen Biotech announced that its subsidiary Hubei Hvsen Biotechnology Co., Ltd. has jointly applied for and obtained the new veterinary drug registration certificate for "Four Seasons Green Extract Powder," which was issued by the Ministry of Agriculture and Rural Affairs on June 9, 2025. The acquisition of this certificate reflects the company's continuous efforts in technological innovation and R&D investment, enriches the variety of traditional Chinese medicine products, meets the requirements for green animal-derived food and animal disease prevention, and enhances market competitiveness

Yinhua CSI Chinese Medicine ETF

Hvsen Biotech: "Four Seasons Green Extract Powder" has obtained a new veterinary drug registration certificate

301335

The pet economy concept has experienced a turbulent decline, with Tianyuan Pet Products and Meino Biotech opening lower and falling nearly 10%. Yuanfei Pet, Daqian Ecology, Hvsen Biotech, and Lusi Co., Ltd. have also seen significant declines

Tianyuan Pet Products

YUANFEI PET

Daqian

MENON

The pet economy concept fluctuates sharply, Tianyuan Pet Products falls nearly 10%

Hvsen Biotech(300871.SZ)